SunGen Pharma Receives Eighth ANDA Approval from FDA

October 31st 2019

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

The approval is for Lidocaine Ointment USP, 5%, used for the production of anesthesia of accessible mucous membranes of the oropharynx.

The product is also used as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns. Lidocaine has annual sales of about 60 million US dollars.

Reference

SunGen Pharma receives eighth ANDA approval from US FDA [news release]. Princeton, NJ; Globe Newswire: October 31, 2019. https://www.globenewswire.com/news-release/2019/10/31/1939048/0/en/SunGen-Pharma-Receives-Eighth-ANDA-Approval-from-US-FDA.html. Accessed October 31, 2019.

Related Content